Phase I trial and tumour localisation of the anti-EGFR monoclonal antibody ICR62 in head and neck or lung cancer.

The purpose of this study was to determine the effect of the first rat monoclonal antibody (MAb ICR62) to the epidermal growth factor receptor (EGFR) in a phase I clinical trial in patients with unresectable squamous cell carcinomas. This antibody effectively blocks the binding of EGF, transforming...

Descripción completa

Detalles Bibliográficos
Autores principales: Modjtahedi, H., Hickish, T., Nicolson, M., Moore, J., Styles, J., Eccles, S., Jackson, E., Salter, J., Sloane, J., Spencer, L., Priest, K., Smith, I., Dean, C., Gore, M.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1996
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2074316/
https://www.ncbi.nlm.nih.gov/pubmed/8546911

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2074316/
https://www.ncbi.nlm.nih.gov/pubmed/8546911

Ejemplares similares